Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma

/PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and...

Related Keywords

Australia ,Taiwan ,United States ,California ,Taipei ,T Ai Pei ,San Diego ,South Korea ,Canada ,John Soong ,Senhwa Biosciences ,Senhwa Bioscience ,Senhwa Biosciences Inc ,Us National Institute Of Health ,Drug Administration ,Cancer Therapy Evaluation Program ,Prnewswire Senhwa Biosciences Inc ,Pediatric Brain Tumor Consortium ,Orphan Drug Designation ,Chief Medical Officer ,Surgical Study ,Therapy Evaluation Program ,Fast Track Designation ,Rare Pediatric Disease ,Priority Review Voucher ,Rare Pediatric Disease Designation ,Sonic Hedgehog ,Nc ,